Dr. Sullivan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Mount Auburn St
Cambridge, MA 02138Phone+1 617-499-5112Fax+1 617-575-8608
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Mount Auburn HospitalResidency, Internal Medicine, 2001 - 2004
Uconn School Of MedicineClass of 2001
Certifications & Licensure
MA State Medical License 2004 - 2025
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021- American Board of Internal Medicine Medical Oncology
Clinical Trials
- An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma Start of enrollment: 2010 Sep 01
- Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma Start of enrollment: 2013 Jan 01
- Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma Start of enrollment: 2014 Mar 24
- Join now to see all
Publications & Presentations
PubMed
- 561 citationsA Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeLivnat Jerby-Arnon, Parin Shah, Michael S. Cuoco, Christopher Rodman, Mei-Ju Su
Cell. 2018-11-01 - 41 citationsThe State of Melanoma: Emergent Challenges and Opportunities.Michael B. Atkins, Clara Curiel-Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao
Clinical Cancer Research. 2021-01-07 - 439 citationsRobust prediction of response to immune checkpoint blockade therapy in metastatic melanomaNoam Auslander, Gao Zhang, Joo Sang Lee, Dennie T. Frederick, Benchun Miao
Nature Medicine. 2018-08-20
Journal Articles
- Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic MelanomaGenevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
- Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic MelanomaRyan J Sullivan, Genevieve Boland, Keith Flaherty, Nature
Lectures
- Debate: Immunotherapy Targeted Therapy Versus Immunotherapy Sequencing — Immunotherapy Sequencing...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Other
- Forestalling BRAF-Inhibitor Resistance in a Shocking WayRyan Sullivan, MD, Clinical Cancer Research
https://www.doximity.com/articles/250420a4-97de-460d-87c1-5ef5e3415ddc
UpToDate, Wolters Kluwer Health - 2013-04-10
Authored Content
- Forestalling BRAF-Inhibitor Resistance in a Shocking WayJuly 2018
- Corrigendum to “Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study*” [Eur J Cancer 91 (2018) 116–124]March 2018
- Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study☆February 2018
Press Mentions
Breakthrough Study Shows Promise for mRNA Cancer VaccinesApril 17th, 2023- In What Could Be a 'Big Shift' for Cancer Treatment, mRNA Vaccine Shows Promise Against MelanomaApril 16th, 2023
- Technology Used in COVID-19 Vaccines Could Treat CancerJune 22nd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
